Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …

The high mortality rate associated with hepatocellular carcinoma (HCC) is partly due to the
high proportion of patients who present with advanced stage disease at diagnosis, for whom …

The preferred treatment for hepatocellular carcinoma (HCC) is surgery, which is the only
way to achieve long-term survival and even a cure. However, the vast majority of patients …

The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the
major challenges to improving prognosis. Neoadjuvant and conversion therapies are …

Background Combination conversion therapies afforded curative surgery chance for initially
unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the …

Downstaging can facilitate liver transplantation (LT) for patients outside of Milan criteria with
hepatocellular carcinoma (HCC); however, the optimal protocol and downstaging outcomes …

Background Recent research has shown that selected patients with initially unresectable
hepatocellular carcinoma (HCC) are able to achieve conversion to resectable disease …

Background Optimal strategies for advanced hepatocellular carcinoma (HCC) tumors, such
as those with vascular tumor thrombus and those with extrahepatic metastases are unclear …

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and
mortality worldwide, largely as a result of 3 main factors:(1) competing risk of cirrhosis, which …

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …